-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3890 Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?

Program: Oral and Poster Abstracts
Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Sickle Cell Disease, Epidemiology, Clinical Research, Health outcomes research, Hemoglobinopathies, Diseases
Monday, December 9, 2024, 6:00 PM-8:00 PM

Thomas D'Humieres, MD1,2*, Mathilde Stevenard3*, Haytham Derbel, MD, PhD4*, Sihem Iles, MD5*, Gonzalo De Luna, MD6,7*, Vania Tacher, MD, PhD8*, Ziana Amorouayeche, MD9*, Anne-Laure Pham Hung D'Alexandry D'Orengiani, PhD10*, Yosr Zaouali11*, Anoosha Habibi, MD12,13,14, Laurent Boyer, MD, PhD15*, Lara Alassaad, MD16*, Henri Guillet, MD17*, Laurent Savale, MD, PhD18*, Geneviève Derumeaux, MD, PhD19* and Pablo Bartolucci, MD, PhD20,21,22*

1CHU Henri Mondor. UPEC. AP-HP, CréTeil, France
2Paris Cardiovascular Research Center - PARCC, Inserm team 8, Paris, France
3Henri Mondor teaching hospital, Physiology department, APHP, Créteil, France
4Radiology Department, Henri Mondor Hospital, Assistance Publique HôPitaux, CréTeil, FRA
5CHU Henri Mondor - AP-HP - FHU SENEC, CréTeil, FRA
6APHP, Paris, France
7Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
8Radiology department, CHU Henri Mondor, APHP, Créteil, France
9Physiology Department, CHU Henri Mondor, CréTeil, FRA
10University Paris-Est-Créteil, IMRB, Inserm U955, Laboratory of excellence LABEX, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Créteil, FRA
11Sickle Cell Referral Center - CHU Henri Mondor, Créteil, France
12Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, Creteil Cedex, France
131 avenue Claude Vellefaux, ERN-EuroBloodNet, PARIS, France
14Sickle Cell Referral Center, Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
15Institut Mondor de Recherche Biomédicale, équipe 08,, Université Paris Est Créteil (UPEC), Creteil, France
16Physiology department, CHU Henri Mondor, APHP, CréTeil, FRA
17Internal medicine department - CHU Henri Mondor - APHP, Créteil, France
18Kremblin Bicêtre teaching hospital, Le Kremlin Bicêtre, FRA
19CHU Henri Mondor, FHU SENEC, Créteil, France
20University Paris-Est-Créteil, IMRB, Inserm U955,, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Creteil, France
21UMGGR French Red Blood Cell Coordinating Referral Center, APHP UPEC IMRB, Créteil, France
22Université Paris-Est Créteil, INSERM U955, IMRB, Laboratory of excellence LABEX GRex, Créteil, France

Background: Sickle Cell Disease (SCD) is linked to various cardiac and systemic vascular disorders, which significantly contribute to both morbidity and mortality. Despite numerous cardiovascular (CV) risk factors, chronic inflammation and endothelial dysfunction, pre-clinical studies suggest a paradoxical protection against atherosclerosis in this population.

Purpose: This study aimed to assess the prevalence of coronary artery disease in homozygous sickle cell disease (SCD) patients - also known as sickle cell anemia (SCA) – at high CV risk, to further identify potential determinants or protective factors.

Methods: From January 2019 to December 2023, consecutive adult patients with SCD were prospectively included in the DREPACOEUR registry at Henri Mondor hospital (Créteil, France), to specifically analyze cardiac structure and function. They all had a comprehensive CV evaluation at steady-state in daycare hospital including clinical exam, cardiac imaging, rhythm monitoring along with biological analysis. For the present study, only SCA patients that underwent coronary imaging (computed tomography (CT) coronary angiogram) were included. Coronary artery disease was defined using coronary calcium score (CS) and CT coronary angiogram score for coronary artery disease (CAD-RADS). For the reader’s information, a CAD-RADS=0 stands for no coronary stenosis while a score >2 refers to a stenosis above 50% and ≥4 to a severe stenosis justifying functional assessment, medical therapy and possibly coronary revascularization. A sample of DREPACOEUR population was then age-matched to a non-SCD population from the same center. Control patients were prospectively enrolled, they had low CV risk, controlled CV risk factors, no type 2 diabetes and no history of coronary artery disease. The entire control cohort underwent CT coronary angiogram using the same equipment, during the same timeframe and with identical acquisition protocol.

Results: Overall, 113 SCA (SS or Sβ0) patients from DREPACOEUR were included. Mean age was 44±12, 48% were male with a high prevalence of systemic hypertension (57%), obstructive sleep apnea (21%) and 12% active smokers. Only one patient had a history of diabetes, and no dyslipidemia (or lipid lowering therapy) was reported. Heart function was mainly preserved with a mean left ventricular ejection fraction (LVEF) of 58±6%. Expectedly, patients displayed low hemoglobin level 8,7±1.4g/dL with high hemolysis markers. Glomerular filtration rate was 109 [62; 122] mL/min/m² with 21% showing chronic kidney disease. Plasmatic LDLc level was surprisingly low (0.7±0.3g/L, with 20% <0.5g/l). Strikingly, no patient showed signs of significant coronary artery disease, with 87% presenting a calcium CS of 0, 77% had CAD-RADS of 0 while no patient was higher than 2 (i.e. coronary stenosis >50%).

Comparison of a subgroup of this cohort with an age-matched non-SCD population (n=62 vs. 82, mean age of 52 years) showed a more extended coronary atherosclerosis in the control group (CS=0 for 77% vs. 52%, p=0.002; CAD-RADS ≥2 for 9 vs. 23%, p=0.02). Coronary angioplasty following CT-scan was performed in 6% of the control group vs. 0% of SCA patients (p=0.046). Multivariate analysis showed that SCA patients were more likely to have systemic hypertension and chronic kidney disease, while the control group showed more obesity (28±5 vs. 24±5kg/m² of BMI) and treated dyslipidemia.

These results prompted us to further explore the determinants of such low LDLc among the DREPACOEUR cohort (n=113). Multivariate linear regression revealed that Age, BMI and total Bilirubin were independently associated with LDLc. Interestingly, only Bilirubin was negatively associated with LDLc (r=-0.35, p<0.001).

Conclusion: Despite multiple CV risk factors, systemic vasculopathy and chronic inflammation, ageing SCA population showed no significant coronary artery disease. These findings align with preclinical studies that suggest bilirubin's lipid-lowering role and its protective effect against atherosclerosis. Furthermore, this study initiates a crucial discussion on the potential impact of hemolysis reduction therapy on atherosclerosis development in SCA patients. Ultimately, these data open new avenues in coronary artery disease pathophysiology understanding, extending far beyond sickle cell disease.

Disclosures: De Luna: Pfizer: Other: Sponsor HEMOPROVE trial NCT05199766; Vertex: Consultancy. Habibi: Novartis: Consultancy; Theravia: Honoraria. Bartolucci: Novartis: Consultancy, Other: member advisory board and member steering commitee; Roche: Consultancy; Pfizer: Consultancy; Bluebird: Consultancy; Addmedica: Consultancy, Other: member advisory board; Emmaus: Consultancy; Innovhem: Other: Founder; JazzPharma: Consultancy.

*signifies non-member of ASH